Dry Eye Prescribing Guidelines

Similar documents
Dry Eye Prescribing Guidelines

Dry Eye Prescribing Guidelines

Dry Eye Syndrome Prescribing Guidelines

Scottish Dry Eye Guidelines

BNF CHAPTER 11: EYE 1 January 2018

Dry eye syndrome is more likely to affect people who are over the age of 60, and the condition is more common among women than men.

Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Dry eye syndrome. Lacrimal gland. Tear duct into nose. 1 of 6

A Compendium of Product information & Indicative manufacturer s prices

OCULAR SURFACE DISEASE SYNDROMES WAYNE ISAEFF, MD LOMA LINDA UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY

Blepharitis. Information for patients Ophthalmology (Emergency Eye Centre) Large Print

Ophthalmic Special Order Products, General Principles

Ophthalmic Special Order Products, General Principles

Bruce H. Koffler, M.D. Lindsay Koffler Cassidy, COT, OSC

Dry Eye. A Closer Look

Ophthalmology Times Case Study Yasmin Mali, MD. Case Study

DRY EYE INFORMATION AND TREATMENTS

11 Eye. To be used in conjunction with NICE guidance/guidelines, the British National Formulary for adults and/or children, and

Package leaflet: Information for the patient. IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin

T a variety of ocular disorders with

HELP HEAL YOUR PATIENTS DRY EYES.

A Non-Randomised, Patient Completed Questionnaire Report.

Dry Eye Syndrome (DES)

Overview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye...

OPHTHALMOLOGY REFERRAL GUIDE FOR GPS

Lecture No. :3 صيدلة سريرية م.د : ضياء جبار

Package Leaflet: Information for the user. NEVANAC 3 mg/ml eye drops, suspension nepafenac

Dry Eyes The mucin layer

John Rawstron Christchurch 2015

Recurrent Corneal Erosion Syndrome

11.Eye Administration of drugs to the eye. Eye drops. Eye ointments. Prescribing of Unlicensed Eye Products

ACULAR EYE DROPS 5 mg/ml Eye Drops

A DRY EYE DISEASE DECISION TREE

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac

Optimizing the Ocular Surface. Presentation Title. Charlene M. Grice, Carolina Eyecare Physicians, LLC

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile) Rx only

CITY UNVERSITY DEPARTMENT OF OPTOMETRY & VISUAL SCIENCE LONDON, UK MODULE - MANAGEMENT OF DRY EYE -Modes of intervention

PATIENT INFORMATION LEAFLET

This indication includes the temporary relief of burning, irritation, and/or discomfort due to dryness of the eye.

Dry Eye Syndrome. A Guide

11.Eye Administration of drugs to the eye. Eye drops. Eye ointments. Prescribing of Unlicensed Eye Products

Case no.4. Subjective. Subjective (2) Caucasian female, 62 Y.O., consulting for a XXX opinion on her condition.

OOGZIEKTEN VOOR DE HUISARTS F. GOES, JR.

Breaking the Cycle. Yijie (Brittany) Lin, MD, MBA, Reena Garg, MD New York Eye and Ear Infirmary of Mount Sinai

Financial Disclosures

CORNEAL CONDITIONS CORNEAL TRANSPLANTATION

No Conflict of Interest to Report Charles Stockwell, O.D

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM RELESTAT, epinastine hydrochloride 0,5 mg/ml, eye drops

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta369

Prevalence of dry eye disease in type 2 diabetic patients and its co-relation with the duration, glycemic control and retinopathy

CASE RECORD :Sterile, Viral, Bacterial Keratitis

Medical and/or Vision Insurance plans do not cover the Specialty Dry Eye Testing or LipiFlow services.

NEVANAC TM 0.1% Eye Drops

PACKAGE LEAFLET: INFORMATION FOR THE USER ACULAR 0.5% w/v EYE DROPS, SOLUTION (Ketorolac trometamol)

Dry Eye Assessment and Management Study ELIGIBILITY OCULAR EVALUATION FORM

Package Leaflet - Information for the User. TOBRADEX 3 mg/ml/1 mg/ml Eye Drops, Suspension Tobramycin and Dexamethasone

A Study of Dry Eye Disorder in Elderly Persons of Western Rajasthan

Learn Connect Succeed. JCAHPO Regional Meetings 2017

Thyroid Eye Disease. Patient & Family Guide

ICD-10 Coding for Contact Lens Problems. The EyeCodingForum.com

Dry Eye and Related Corneal Issues. Outline. Dry Eye Syndrome (DES)

Kerato-Conjunctivitis Sicca or Dry Eye

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

Package leaflet: Information for the user. Carmellose sodium

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin

VOLTAREN OPHTHA Eye Drops 0.1%

Ocular Allergy. Phil Lieberman, MD

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

Title: Keeping Step with DEWS2: Clinical Applications Lecturer: Scott G. Hauswirth, OD

JMSCR Vol 05 Issue 02 Page February 2017

Proton Pump Inhibitor De-prescribing Guidance

1998 DESCRIPTION Evaluation of Subjective and Objective tests for diagnosing tear-film disorders known to cause ocular irritation.

Meibomian Gland Dysfunction: What Does It Mean James P. McCulley, MD, FACS, FRCOph(UK)

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

A Clinical Study of Ocular Surface Diseases and their Management

Advanced Diagnosis and Management of OSD and Tear Dysfunction

Developed by Ipswich Hospital NHS Trust and Ipswich and East Suffolk Clinical Commissioning Group. Joint formulary - Ophthalmology

Does in-office manual expression for Meibomian Gland Dysfunction (MGD) work?

Evaluation of Dry Eye: A Hospital Based Study

SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM

Package leaflet: Information for the user. Xalatan 50 micrograms/ml Eye drops, solution Latanoprost

Bill Kilgore, LDO,NCLE,COA Virginia Mason Medical Center

Topical eye medication: dialogue, drops & directing Professor Chris Purslow

MURINE HAYFEVER RELIEF 2% W/V EYE DROPS Sodium Cromoglicate

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES

Allergic Conjunctivitis

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

LUMIGAN EYE DROPS (bimatoprost 0.3 mg per ml)

INDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.

Dr Jo-Anne Pon. Dr Sean Every. 8:30-9:25 WS #70: Eye Essentials for GPs 9:35-10:30 WS #80: Eye Essentials for GPs (Repeated)

Question 1: Discuss your further examination of this patient with respect to her current symptoms

Acute Eyes for ED. Enis Kocak. The Alfred Ophthalmology

Current Practice Pattern for Dry Eye Patients in South Korea: A Multicenter Study

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM LUMIGAN 0,01 %, bimatoprost 0,1 mg/ml eye drops

The first comprehensive definition of DED was published in

Proposed PIL NL/H/0653/001/IB/024/G. MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate

Dr.Sushil Kumar Tripathi

Transcription:

Dry Eye Prescribing Guidelines Amendment History VERSION DATE AMENDMENT HISTORY V1.0 2011 Comments V1.1 2013 Updated V1.1 2017 Draft Updated Thealoz Duo replaces carmellose Optive in severe dry eye on the previous pathway. This would replace sodium hyaluronidate 0.2%, clinitas 0.4% as it is more cost effective. V2.0 June 2017 Final version ratified REVIEWERS This document had been reviewed by: NAME DATE TITLE/RESPONSIBILITY VERSION ACE Assurance Framework for managing clinical policies and guidelines 8 APPROVALS This document has been approved by: NAME DATE TITLE/RESPONSIBILITY VERSION Review date NB: The version of this policy posted on the intranet/internet must be a PDF copy of the approved version. DOCUMENT STATUS This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of the document are not controlled. RELATED DOCUMENTS These documents will provide additional information: REFERENCE NUMBER DOCUMENT TITLE VERSION

APPLICABLE LEGISLATION N/A GLOSSARY OF TERMS TERM ACRONYM DEFINITION Clinical Commissioning CCG Group Area Clinical Effectiveness Committee ACE Alison Whitlock Mr M Quinlan Mr M Parbat Authors DGoH Pharmacist for Opthalmology DGoH Consultant Opthalmologist Dudley CCG Prescribing Advisor

DRY EYE SYNDROME Dry eye syndrome is a multifactorial disease of the tears and ocular surface that results in a range of symptoms, including discomfort, visual disturbance, tear film instability and potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. The key features of dry eye syndrome are: Decreased tear production Increased tear evaporation Incorrect composition of tears These result in inadequate lubrication of the eyes. Symptoms Patients typically present with: feelings of dryness, grittiness, foreign body sensation, red eyes, staining of cornea, or soreness in both eyes, which get worse throughout the day eyes water, particularly when exposed to wind, and reflex tearing or blurring whilst reading or driving eyelids stuck together on waking Causes Dry eye syndrome prevalence increases with age (15-33% in people 65+ years); 50% more common in women than in men; a frequent complaint in post-menopausal women and rheumatoid patients. It is an extremely common eye condition and has a wide range of causes, including: Decreased tear production: blepharitis (most common cause) tear film instability; adverse effect of systemic drugs (e.g.: antihistamines, tricyclic antidepressants, SSRIs; preservatives in topical eye medications); allergic conjunctivitis; dehydration (e.g. secondary to diabetes) Increased evaporation of tears - environmental factors at home / work (less commonly, caused by Lagophthalmos)/ most commonly with meibomian gland dysfunction Abnormal ocular surface / disruption of the afferent sensory nerves Decreased lipid production by Meibomian glands Underlying conditions associated with dry eye syndrome include: allergic conjunctivitis Sjögren's syndrome (ask about dry mouth) Rheumathoid arthritis Rosacea (or ocular rosacea with inflammation and meibomian secretion abnormality) facial or trigeminal neuropathy herpes zoster affecting the eye chronic dermatoses of eyelids

previous ocular or eyelid surgery, trauma, radiation therapy, burns Less commonly, people present with a complication of dry eye syndrome, e.g.: Conjunctivitis Ulceration of the cornea, suggested by severe pain, photophobia, marked redness, and loss of visual acuity General management Treatment should initially focus on identifying and addressing lifestyle/environmental factors that may cause or exacerbate dry eye syndrome. The patient's medication history should also be reviewed, as topical and systemic antihistamines have been associated with dry eye syndrome. Similarly, HRT, TCAs and SSRIs can aggravate ocular symptoms. Reassure - when there is no underlying medical condition, most people with dry eyes have only discomfort and no lasting loss of vision though visual symptoms are common as severity increases. Rarely, the cornea develops ulcers. Mucus filaments adhere and may be painful in more severe forms. Treatment Artificial tears alone are usually sufficient to provide relief for mild dry eye and can be bought by the patient without a prescription. Hypromellose is a widely used product,. Products containing carbomers or polyvinyl alcohol are longer-acting. Sodium Hyaluronate is becoming more widely used because of its waterretaining properties and low resistance to blinking (viscoelastic property). If the patient has known allergy to preservative consider switching to one that is preservative-free. Products that do not contain preservatives are packed as single doses and are more expensive than multi-dose preparations in most cases but are more suitable where frequent use is needed or ocular surface disturbance is significant. Preservative drops are not compatible with contact lenses contact lens wearers should get advice from their optometrist. Eye ointments - such as paraffins - physically lubricate and protect the eye surface from epithelial erosion and are particularly useful when the eye is closed during sleep. Eye ointments containing paraffin may be uncomfortable and blur vision, they should only be used at night and never with contact lenses some alternatives are available. Where ointments are too greasy carbomers or combination carbomer with lipid are available (artelac nightime gel) Significant ocular surface disturbance may require specialist advice and treatment in the corneal service.

Severity Symptoms & Signs Treatment Options Mild Moderate Severe Discomfort: mild Frequency of discomfort: episodic Visual symptoms: nil/mild Corneal staining with fluorescein: nil/min Conjunctival staining: nil/min FBUT variable Schirmer test variable Discomfort: moderate Frequency of discomfort: episodic or chronic Visual symptoms: episodic, limiting activity Corneal staining with fluorescein: variable Conjunctival staining: variable FBUT < 10 seconds Discomfort: Schirmer test severe < 10mm at 5 mins Frequency of discomfort: constant/disabling Visual symptoms: constant, activity limiting and disabling Corneal staining with fluorescein: marked severe puntate erosions Conjunctival staining: moderate to marked Corneal signs: mucus filaments or clumping, increased tear debris, corneal ulceration FBUT < 5 seconds Schirmer test < 5mm at 5mins Hypromellose 0.3%/0.5% Carbomer eye drops (Cetrimide preservative) Hydroxypropyl gum (Systane Ultra) Optive Fusion* Optive Fusion * Sod. Hyaluronate 0.15% (Hyabak) RP* Carmellose 1% * VitaPOS/ Liquid paraffin eye ointment for use at night Artelac Night-time gel (carbomer/triglyceride) + Sod.hyaluronate 0.2% (Hyloforte) RP* Sod.hyaluronate 0.4%(Clinitas)* # Hydroxypropyl gum (Systane Ultra unit dose) Specialist Initiation/recommendation only Theoloz Duo ( Trehalose, Sodium hyaluronidate) * Products suitable for patients who cannot tolerate preservatives. # Clinitas dose units can be reclosed for up to 12 hours with multiple applications. R Hyabak and Hyloforte are supplied in a soft bottle that some patients may find easier to squeeze such as those rheumatoid arthritis. P phosphate free buffered solutions Where severe ocular surface disease is encountered and/or calcium deposition has occurred a nonphosphate buffered preparation should be considered (Hyabak or Hyloforte) though response to treatment will need reviewed and phosphate buffered solutions should still be considered in these circumstances. Specialist preparations may be necessary but are monitored in the hospital based service + When ointments are too greasy/poorly tolerated. Meibomian gland dysfunction predominates Optive plus or Systane balance

Other special agents (monitored in corneal and external diseases clinic) Specialist Initiation/recommendation only Acetylcysteine Preservative free steroids Ciclosporin 1mg/ml (Ikervis) unit dose (approved by NICE for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes) Manual dexterity If patient has difficulty administering drops due to reduced manual dexterity consider carbomer gel. Hyabak and Hyloforte are supplied in a soft bottle that some patients may find easier to squeeze such as those with rheumatoid arthritis. Eye hygiene If meibomian gland dysfunction is present, hot compresses (e.g. clean flannel rinsed in hot water) may benefit. Microwaveable mask. Eyelid hygiene will also help to control the blepharitis that most people with dry eye syndrome have. Environment and other measures Advise patients to minimise environmental and other factors that aggravate dry eye syndrome: if smokers, try to stop as it exacerbates symptoms avoid air conditioning take regular breaks if use computer for long periods / avoid staring at the screen for long periods wear wrap-around glasses outside. Omega 3 fatty acid supplements may be of help in blepharits (self purchase supplements) References 1. Behrens A, Doyle JJ, Stern L et al. Dysfunctional tear syndrome A Delphi approach to treatment recommendations. Cornea 2006 25:900-7 2. Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international dry eye workshop (2007). Ocul Surf 2007;5(2): 163-178. 3. Ophthalmology Referral Guidelines, Oxfordshire PCT, March 2012 4. Clinical Knowledge Summaries http://www.cks.nhs.uk/dryeyesyndrome#-320107

Drug Name Indications Dose Proprietary name CARBOMERS (Polyacrylic acid) dry eyes including keratoconjunctivitis sicca, unstable tear film Apply 3 4 times daily or as required Benzalkonium containing products should be prescribed by BRAND Ingredients Excipients Pack Size Price* Clinitas Gel carbomer 980 (polyacrylic acid) 0.2% 10 g 1.49 Viscotears Lumecare Long Lasting Tear Gel Carbomer '980' 0.2% eye drops GelTears Liposic Artelac Nighttime gel carbomer 980 (polyacrylic acid) 0.2% carbomer 980 (polyacrylic acid) 0.2% Carbomer '980' 0.2% carbomer 980 (polyacrylic acid) 0.2% carbomer 980 (polyacrylic acid) 0.2% Carbomer 0.2%, Medium Chain Triglycerides cetrimide 10g 1.59 cetrimide 10g 1.51 benzalkonium 10g 2.80 benzalkonium 10g 2.80 cetrimide 10g 2.96 Cetrimide 10g 2.96 Liquivisc carbomer 974P (polyacrylic acid) 0.25% benzalkonium 10g 4.50 Viscotears carbomer 980 (polyacrylic acid) 0.2% 30 0.6-mL 5.42 CARMELLOSE SODIUM dry eye conditions Apply as required Carmellose carmellose sodium 1% 30 x 0.4 ml 3.00 Celluvisc carmellose sodium 1% 30 x 0.4 ml 3.00 Carmize carmellose sodium 1% 30 x 0.4 ml 3.00 Carmellose carmellose sodium 0.5% 30 x 0.4 ml 5.75 Carmize carmellose sodium 0.5% 30 x 0.4 ml 5.75

Celluvisc carmellose sodium 0.5% 30 x 0.4 ml 4.80 Optive carmellose sodium 0.5%, glycerol 10ml 7.49 Optive Plus (for meibomian gland dysfunction) Carmellose sodium 0.5%, Castor oil 1%, Glycerin 0.25% 10ml 7.49 HYPROMELLOSE tear deficiency Apply as required Isopto Plain hypromellose 0.5% benzalkonium Isopto Alkaline hypromellose 1% benzalkonium Hypromellose hypromellose 0.3% benzalkonium Tears Naturale hypromellose 0.3%, benzalkonium dextran 70 0.1%, disodium edetate Artelac hypromellose 0.32% cetrimide, disodium Lumecare Preservative Free Tear Drops 10ml 10ml 10ml 1.42 10ml 2.99 10ml 4.60 edetate hypromellose 0.3% 30 0.5 ml 5.72 Tear-Lac hypromellose 0.3% 10ml 5.75 Hydromoor hypromellose 0.3% 30 x 0.4 ml 5.75 Tears Naturale hypromellose 0.3%, dextran 70 0.1% 28 0.4 ml 13.26 Single Dose Artelac SDU hypromellose 0.32% 30 0.5 ml 16.95 81p 94p LIQUID PARAFFIN dry eye conditions Apply as required VitA-POS (expiry of 3 months once opened) Retinol palmitate 250 units/g, white soft paraffin, light liquid paraffin, liquid paraffin, wool fat 5g 2.75

dry eye conditions Apply as required Lacrilube Liquid paraffin 425 mg per 1 gram White soft paraffin 573 mg per 1 gram Wool alcohols 2 mg per 1 gram dry eye conditions Apply as required Xailin night White soft paraffin, white mineral oil, lanolin alcohols 3.5-5g 2.94-3.88 5g 2.49 MACROGOLS (Polyethylene glycols) dry eye conditions Apply as required Systane Ultra polyethylene glycol 400 0.4%, propylene glycol 0.3%, hydroxypropyl guar 10ml 6.69 Hydroxypropyl Guar Systane Ultra polyethylene glycol 400 0.4%, propylene glycol 0.3%, hydroxypropyl guar 30 0.7 ml 6.69 Systane Balance polyethylene glycol 400 0.6% 10ml 7.49 SODIUM HYALURONATE dry eye conditions Apply as required Oxyal sodium hyaluronate 0.15% 10ml 4.15 Due to differences in chain length and viscosity the strengths do not indicate equivalence * Prices as per BNF 72 (September 2016 - March- 2017) http://www.bnf.org/bnf/index.htm Lubristil sodium hyaluronate 0.15% 20 x 0.3 ml 4.99 Ocusan sodium hyaluronate 0.2% 20 0.5 ml 5.25 Clinitas sodium hyaluronate 0.4% Note Each unit is resealable and may be used for up to 12 hours 30 0.5 ml 5.37 Hyabak sodium hyaluronate 0.15% 10ml 7.99 Hylo-Forte sodium hyaluronate 0.2% 10ml 9.50